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Abstract
Background: Accurate prevalence data are important when interpreting diagnostic tests and planning for the
health needs of a population, yet no such data exist for axial spondyloarthritis (axSpA) in the UK. In this cross-sectional
cohort study we aimed to estimate the prevalence of axSpA in a UK primary care population.
Methods: A validated self-completed questionnaire was used to screen primary care patients with low back pain
for inflammatory back pain (IBP). Patients with a verifiable pre-existing diagnosis of axSpA were included as positive cases.
All other patients meeting the Assessment of SpondyloArthritis international Society (ASAS) IBP criteria were
invited to undergo further assessment including MRI scanning, allowing classification according to the European
Spondyloarthropathy Study Group (ESSG) and ASAS axSpA criteria, and the modified New York (mNY) criteria for
ankylosing spondylitis (AS).
Results: Of 978 questionnaires sent to potential participants 505 were returned (response rate 51.6 %). Six subjects had
a prior diagnosis of axSpA, 4 of whom met mNY criteria. Thirty eight of 75 subjects meeting ASAS IBP criteria attended
review (mean age 53.5 years, 37 % male). The number of subjects satisfying classification criteria was 23 for ESSG,
3 for ASAS (2 clinical, 1 radiological) and 1 for mNY criteria. This equates to a prevalence of 5.3 % (95 % CI 4.0, 6.8) using
ESSG, 1.3 % (95 % CI 0.8, 2.3) using ASAS, 0.66 % (95 % CI 0.28, 1.3) using mNY criteria in chronic back pain patients, and
1.2 % (95 % CI 0.9, 1.4) using ESSG, 0.3 % (95 % CI 0.13, 0.48) using ASAS, 0.15 % (95 % CI 0.02, 0.27) using mNY criteria
in the general adult primary care population.
Conclusions: These are the first prevalence estimates for axSpA in the UK, and will be of importance in planning for
the future healthcare needs of this population.
Trial registration: Current Controlled Trials ISRCTN76873217
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Background
Accurate estimates of disease prevalence are important
when planning for future health needs, yet no contem-
porary data exist for axial spondyloarthritis (axSpA) or
ankylosing spondylitis (AS) in the UK. The only general
population studies date from the late 1950s, several years
before the first AS classification criteria (the Rome cri-
teria) were adopted. [1, 2] In Underwood and Dawes'
1995 study 313 patients with chronic back pain in pri-
mary care were screened for inflammatory back pain,
with those scoring positively then examined clinically
and radiologically. [3] Two patients had AS and 18 (5 %)
had at least one feature associated with SpA, but no esti-
mates of prevalence in the general population could be
made.
Understanding of the spectrum of axSpA/AS has chan-
ged considerably in the past decade, with MRI changes
encapsulated into the Assessment of Spondyloarthritis
International Society (ASAS) classification criteria. [4]
However, to date no European studies have estimated
disease prevalence using MRI data. In this study we in-
vestigated the prevalence of axSpA in a UK primary
care cohort by applying contemporary classification cri-
teria and imaging modalities to patients with inflamma-
tory back pain (IBP) - the earliest and commonest
symptom of axSpA. [5]
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Methods
The setting was a large general practice in Norfolk, UK,
with 17,000 patients at the time of the study. Potential
participants were patients aged 18–80 who had at any
time consulted their general practitioner with low back
pain. Patients were identified through a READ code
search of electronic health records and were excluded
from the study if they lived in a nursing home or had a
terminal illness. A validated screening questionnaire for
axSpA [6] was sent to a random sample of those eligible
(all patients whose surnames began with A-G or J). Poten-
tial participants were selected pragmatically on the basis
of first letter of surname, as the surgery computer system
was not configured to allow stratification by other means
such as age decile or postcode. A further questionnaire
was sent to non-responders.
Respondents with a pre-existing diagnosis of axSpA or
AS (verified from hospital or GP records) were included
as positive cases. All others whose questionnaire re-
sponses indicated they met the ASAS IBP classification
criteria were invited for clinical review. This included a
detailed history and physical examination by a rheuma-
tologist, and blood testing for HLA-B27. All subjects were
invited to undergo an MRI scan of the whole spine and
sacroiliac joints, according to the Spondyloarthritis Re-
search Consortium Canada (SPARCC) protocol (http://
www.arthritisdoctor.ca/mri.php). Scans were reported by
an experienced musculoskeletal radiologist blinded to the
clinical data. Subjects were classified according to the
European Spondyloarthropathy Study Group (ESSG)
SpA criteria [7], the ASAS axSpA criteria (clinical and
radiological arms) [4] and the modified New York (mNY)
criteria for AS [8] (Table 1).
The sample size calculation for the initial survey as-
sumed the prevalence of axSpA in chronic back pain
patients to be 3–7 %, with a confidence level of 95 %. The
recruitment target was 457 but as the response rate to a
postal survey would not be expected to exceed 50 % we
aimed to approach around 1000 potential participants.
Ethical approval for the study was granted by the
Norfolk Research Ethics Committee, and written con-
sent was obtained from participants prior to clinical
review. Data were analysed using PASW 18 and Micro-
soft Excel. Confidence intervals for the population
prevalence estimates were obtained using bootstrapping
in Stata (version 12).
Results
Recruitment through each stage of the study is shown in
Fig. 1. The initial search found over 3000 individuals
who had consulted on at least one occasion with low
back pain. This represented 22.4 % of the total adult
practice population. From this pool of potential partici-
pants, questionnaires were sent to a random sample of
978 people with 505 questionnaires returned (response
rate 51.6 %). The prevalence of IBP in this cohort has
Table 1 SpA classification criteria
ESSG ASAS mNY criteria
Inflammatory spinal pain OR synovitis
(asymmetric or predominantly lower limb)
Sacroiliitis on imaging plus≥ 1 SpA feature
OR HLA-B27 plus≥ 2 other SpA features
Definite AS if radiological criterion is associated
with at least one clinical criterion.
AND one or more of the following: Clinical criteria:
• Positive family history SpA features: • Low back pain and stiffness for > 3 months
that improves with exercise but is not relieved
by rest.
• Psoriasis Inflammatory back pain,
• Inflammatory bowel disease arthritis, enthesitis (heel), uveitis, dactylitis,
• Urethritis, cervicitis or acute
diarrhoea within 1 month before
arthritis
psoriasis, Crohns/colitis, good response to NSAIDs,
family history for SpA, HLA-B27, elevated CRP
• Limitation of motion of the lumbar spine in the
sagittal and frontal planes.
• Buttock pain alternating between
right and left gluteal areas
• Limitation of chest expansion relative to normal
values correlated for age and sex.
• Enthesopathy
• Sacroiliitis
Sacroiliitis on imaging:
Definite radiographic sacroiliitis according to
mNY criteria.
Radiological criterion:
OR
Active (acute) inflammation on MRI highly
suggestive of sacroiliitis associated with SpA.
• Sacroiliitis grade≥ 2 bilaterally or 3–4 unilaterally.
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been reported previously [9]. Respondents were signifi-
cantly older than all potential participants (mean age
(95 % CI) 57.5 years (56.4, 58.6) versus 53.2 years (52.2,
54.1) but there was no gender difference (Χ2p = 0.27).
Despite being selected on the basis of a single consult-
ation, 80 % of respondents reported pain lasting for at
least 3 months.
Six respondents had a pre-existing diagnosis of axSpA
(one woman and 3 men met mNY criteria; 2 women
met ASAS axSpA criteria, 1 through the clinical arm
and one the radiological arm). Of 75 additional subjects
who met the ASAS IBP criteria in their questionnaire
responses, 38 attended a clinical review appointment.
The mean age of clinical review participants was 53.5 years,
and 37 % were male. All were white British, with 2 (5 %)
positive for HLA-B27. There was no significant difference
in age or gender between those who agreed to attend a
clinical assessment and the 75 invited (t-test p = 0.443 and
Χ2 test p = 0.888 respectively).
MRI was undertaken in the 31 subjects who con-
sented and had no contra-indication. The prevalence of
bone marrow oedema on MRI was low, with clinically
significant inflammatory change seen in only one sub-
ject (3 %). Despite having typical symptoms meeting
the ASAS IBP criteria, 14 (45 %) had only degenerative
changes on MRI and 11 (35 %) had a normal scan.
Fifteen respondents self-reported a diagnosis of AS,
but on review of primary care and hospital records had
other conditions entirely, including spondylosis, osteope-
nia and polymyalgia rheumatica. As a control, 16 re-
spondents with ‘mechanical’ back pain (not meeting any
of the IBP criteria) were assessed, one of whom fulfilled
ASAS axSpA criteria through the clinical arm. However,
this subject was felt to meet the ASAS IBP classification
criteria when his symptoms were reviewed face-to-face.
The mean Bath Ankylosing Spondylitis Activity Index
(BASDAI) in the 38 subjects with IBP was 3.89, versus
4.91 in the 16 controls (p = 0.133), with a mean Ankylos-
ing Spondylitis Quality of Life (ASQoL) score of 4.92 in
the subjects versus 6.75 in the controls (p = 0.269).
Prevalence of axSpA
ESSG
Following clinical review, 23 of the 38 attendees met
the ESSG classification criteria (see Table 2). There was
no significant gender difference amongst those fulfilling
the criteria (Χ2 test p = 0.503). Despite the mean age of
participants, 21/23 (91 %) had onset of back pain by
45 years. Assuming the attendees to be representative, 45
of the 75 respondents identified with IBP would be ex-
pected to meet ESSG criteria. Including the six individuals
with a pre-existing diagnosis, this equates to a minimum
prevalence of ESSG-defined SpA of 5.3 % (95 % CI 4.0,
6.8) among adults aged 18–80 with chronic low back pain.
Extrapolating to the adult practice population, the mini-
mum prevalence of ESSG-defined SpA can be estimated
at 1.2 % (95 % CI 0.9, 1.4).
ASAS axSpA
Three subjects satisfied the ASAS axSpA criteria (one
through the radiological arm and 2 the clinical arm). In-
cluding the six respondents with a pre-existing diagnosis
this equates to an estimated minimum prevalence of
ASAS-defined axSpA of 1.3 % (95 % CI 0.8, 2.3) in
adults with chronic back pain and 0.3 % (95 % CI 0.13,
0.48) in the adult primary care population.
mNY criteria
One of the three subjects who fulfilled ASAS axSpA cri-
teria also met mNY criteria (radiographs of the sacroiliac
joints having been performed outwith the study), as did
four respondents with a pre-existing diagnosis. This
equates to a minimum AS prevalence of 0.66 % (95 % CI
0.28, 1.3) amongst those with chronic low back pain. Ex-
trapolated to the general practice population, the preva-
lence is 0.15 % (95 % CI 0.02, 0.27).
Discussion
This study has estimated the prevalence of axSpA in a
primary care population to be 1.2 % using ESSG criteria,
Fig. 1 Recruitment of participants at each stage of the study
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0.3 % using ASAS criteria, and 0.15 % using mNY cri-
teria. These are the first such estimates for axial SpA in
the UK, and will be important when planning the
provision of health services for these patients. Previous
European studies using ESSG criteria have provided
similar estimates of 0.3 % [10] – 1.06 % [11], while the
prevalence of axSpA meeting ASAS criteria (without
MRI imaging) in a recent French cohort was 0.43 % [12].
The mNY criteria – in common with all classification
criteria – were developed by characterising patients
with definite disease. In axSpA, this means patients at
the extreme end of the spectrum with significant radio-
graphic damage, which might only manifest a decade or
more after symptom-onset. [13] The ASAS criteria
were intended to improve sensitivity in early disease,
and as well as the ‘radiographic’ group classify as axSpA
those with MRI-defined sacroiliitis and patients who are
HLA-B27 positive and have clinical features of axSpA but
no definite radiological abnormalities. This ‘clinical arm’
of the criteria has proven controversial, with concerns that
patients with other conditions such as fibromyalgia could
be misclassified as having axSpA. Furthermore axSpA as a
concept doesn’t necessarily equate with ‘early AS’; the pro-
portion of patients with axSpA who eventually meet mNY
criteria ranges from 14 to 59 % in the literature. [13, 14]
While the ESSG criteria are also better at classifying early
disease, their specificity in real-life situations is limited. Of
28 patients in a Spanish study meeting ESSG criteria, only
13 had clinician-confirmed SpA at 5 years [15]. However,
most studies of SpA prevalence have used the ESSG cri-
teria to classify cases, and including them in this study
allowed direct comparison to be made with previous stud-
ies. The ESSG criteria can also be fulfilled by patients with
peripheral spondyloarthropathy, so using them alone
might over-estimate the prevalence of axial disease in the
community. This is less likely to be an issue in our study
where back pain was the initial screening question and no
patients had peripheral arthritis on review.
The main limitation in the study design is the risk of
selection bias at each sampling stage, potentially leading
to overestimation of disease prevalence. While the
demographic characteristics of respondents and non-
respondents were similar, we have no information on
the symptom severity of non-attenders. The assumption
is that participants would be driven to attend review and
MRI appointments by more intrusive symptoms, al-
though this does not necessarily equate to more axial
SpA. The majority of patients with IBP had no changes
or only degenerative changes on MRI, and patients with
mechanical pain had similar patient-reported outcome
measure scores to those with inflammatory-type pain.
The population prevalence estimates in this study are
minimum values, with two assumptions: that none of
the non-responders to the questionnaire had IBP or by
extension axSpA, and that the 22.4 % of patients who
had consulted with back pain included all the cases of
axSpA (diagnosed and undiagnosed) in the practice.
While up to 30 % of patients with physician-diagnosed
early axSpA might have non-inflammatory back pain
[16], the proportion in this study was much smaller and
there is unlikely to have been a significant underestima-
tion of prevalence resulting from the review of patients
with IBP rather than chronic back pain per se. Although
the absolute numbers in the imaging phase were small,
the sample size was sufficient to assess the prevalence of
axSpA with reasonable precision, and allowed three sub-
jects with previously unsuspected disease to be classified
as having axSpA. This represents one third of those who
fulfilled the ASAS axSpA criteria by the end of the
study.
Fewer than 10 % of people in this study who met the
ASAS IBP criteria fulfilled the ASAS axSpA criteria. This
is in contrast to primary care screening studies such as
the RADAR [17] and MASTER [18] studies where the
proportion with physician-diagnosed SpA was consist-
ently around 40 %. Similarly a recent Dutch study
showed 1 in 4 young patients with chronic low back pain
met the ASAS axSpA criteria. [19] Referral studies, in
which patients meeting pre-specified criteria are triaged
for further investigation, tend to exclude those aged over
Table 2 Number of individuals meeting axSpA criteria stratified by age and gender
Age band Subjects sent screening
questionnaire
ASAS IBP + ve Subjects seen for clinical
review
ESSG + ve ASAS + ve mNY criteria + ve
Male Female Male Female Male Female Male Female Male Female Male Female
20–29 27 (2.8 %) 44 (4.5 %) 1 (1 %) 1 (1 %) 0 (0 %) 1 (3 %) 0 (0 %) 1 (4 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
30–39 58 (5.9 %) 67 (6.8 %) 5 (7 %) 8 (11 %) 2 (5 %) 3 (8 %) 0 (0 %) 2 (9 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
40–49 94 (9.6 %) 98 (10.0 %) 4 (5 %) 12 (16 %) 3 (8 %) 7 (18 %) 1 (4 %) 4 (17 %) 1(33 %) 0 (0 %) 0 (0 %) 0 (0 %)
50–59 107(10.9 %) 109 (11.1 %) 8 (11 %) 14 (19 %) 3 (8 %) 6 (16 %) 2 (9 %) 5 (22 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
60–69 116 (11.9 %) 114 (11.7 %) 6 (8 %) 9 (12 %) 3 (8 %) 4 (11 %) 2 (9 %) 2 (9 %) 1 (33 %) 0 (0 %) 0 (0 %) 0 (0 %)
70–79 65 (6.6 %) 79 (8.1 %) 4 (5 %) 3 (4 %) 3 (8 %) 3 (8 %) 2 (9 %) 2 (9 %) 1 (33 %) 0 (0 %) 1 (100 %) 0 (0 %)
Total 467 511 28 47 14 24 7 16 3 0 1 0
Hamilton et al. BMC Musculoskeletal Disorders  (2015) 16:392 Page 4 of 5
45 years which may be a factor, although the populations
are different in other ways. In the RADAR and MASTER
studies primary care physicians were incentivised to
refer to specialist centres with an interest in axSpA,
and awareness of the condition was already heightened
amongst patients and doctors. In contrast our study
recruited participants from the general primary care
population, few of whom were seeking current medical
attention for their pain, and where knowledge of AS
was low given the number of respondents who mistakenly
believed they had the condition. We believe the 10 % rate
of axSpA is likely to better reflect the true frequency
among people with inflammatory-type back pain.
Conclusions
These are the first UK estimates of axSpA prevalence in
general practice using contemporary criteria. The findings
suggest there is a hidden burden of axSpA and even AS in
primary care. Given the excellent treatment outcomes ob-
served for axSpA with new therapies, there is an urgent
need to refine clinical assessment tools to detect axSpA
specifically for use in the population setting.
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